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Tumor models based on cancer cell lines cultured two-dimensionally (2D) on plastic lack histological com-
plexity and functionality compared to the native microenvironment. Xenogenic mouse tumor models display
higher complexity but often do not predict human drug responses accurately due to species-specific differences.
We present here a three-dimensional (3D) in vitro colon cancer model based on a biological scaffold derived
from decellularized porcine jejunum (small intestine submucosa+mucosa, SISmuc). Two different cell lines
were used in monoculture or in coculture with primary fibroblasts. After 14 days of culture, we demonstrated a
close contact of human Caco2 colon cancer cells with the preserved basement membrane on an ultrastructural
level as well as morphological characteristics of a well-differentiated epithelium. To generate a tissue-
engineered tumor model, we chose human SW480 colon cancer cells, a reportedly malignant cell line.
Malignant characteristics were confirmed in 2D cell culture: SW480 cells showed higher vimentin and lower E-
cadherin expression than Caco2 cells. In contrast to Caco2, SW480 cells displayed cancerous characteristics
such as delocalized E-cadherin and nuclear location of b-catenin in a subset of cells. One central drawback of
2D cultures—especially in consideration of drug testing—is their artificially high proliferation. In our 3D
tissue-engineered tumor model, both cell lines showed decreased numbers of proliferating cells, thus correlating
more precisely with observations of primary colon cancer in all stages (UICC I-IV). Moreover, vimentin
decreased in SW480 colon cancer cells, indicating a mesenchymal to epithelial transition process, attributed
to metastasis formation. Only SW480 cells cocultured with fibroblasts induced the formation of tumor-like
aggregates surrounded by fibroblasts, whereas in Caco2 cocultures, a separate Caco2 cell layer was formed
separated from the fibroblast compartment beneath. To foster tissue generation, a bioreactor was con-
structed for dynamic culture approaches. This induced a close tissue-like association of cultured tumor cells
with fibroblasts reflecting tumor biopsies. Therapy with 5-fluorouracil (5-FU) was effective only in 3D
coculture. In conclusion, our 3D tumor model reflects human tissue-related tumor characteristics, including
lower tumor cell proliferation. It is now available for drug testing in metastatic context—especially for
substances targeting tumor–stroma interactions.
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Introduction
Cancer is a leading cause of death worldwide, espe-cially in developed countries, and will gain importance
with the progressing age structure of future society. Success in
the treatment of this disease depends on the development of
appropriate tumor models to improve the translation of novel
treatment strategies from research to the patients’ situation.
Especially in the field of oncology, attrition rates attain up to
95%.1 Reasons are that tumorigenesis is not only regulated
intrinsically by genetic changes in the tumor cell itself but also
by microenvironmental cues and stromal cell-to-cell interac-
tions that instruct tumor development.2,3 These conditions are
poorly reproduced by conventional two-dimensional (2D) cell
culture models currently used in drug development.
Three-dimensional (3D) cell culture approaches such as
Matrigel coating and spheroid cultures have gained impor-
tance and substantially improved in vitro tumor models.2,4
Tissue engineering offers attractive options for innovative 3D
scaffolds that correspond more closely to native tumors than
standard 2D cell culture systems or animal models.5 How-
ever, a crucial step in cancer progression neglected in most
models is the invasion across the basement membrane, a
process that starts metastasis formation and mostly excludes
patients from complete remission under therapy.
Epithelial cancers—known as carcinomas—can become in-
vasive bymainly two differentmechanisms: (1) single tumor cell
invasion, mostly preceded by an epithelial-to-mesenchymal
transition (EMT), through which cells lose epithelial and gain
mesenchymal markers and (2) collective tumor cell invasion,
probablydrivenbycancer-associatedfibroblasts and independent
of EMT.6,7 In this study, fibroblasts associate closely with tumor
cells, serve as guidance, digest thematrix, and ultimately deposit
extracellular matrix (ECM) components to form a complex, tu-
mor–stroma.8,9Metastasis formation shows a reverse programof
EMT called mesenchymal-to-epithelial transition (MET).10
To generate tissue-engineered tumors, including tumor–
stroma, in a biological tissue architecture, we use a decel-
lularized part of the porcine jejunum derived from the patented
Biological Vascularized Scaffold (DE:302014007893; Bio-
VaSc) structure. We define our scaffold as ‘‘small intestinal
submucosa with preserved mucosa’’ (SISmuc). It differs from
the commonly used SIS scaffolds11 by the preservation of the
mucosal tissue layer, including crypt, villi, and the basement
membrane structures.12 This allows us to investigate the pro-
cess of invasion of tumor cells across the basement membrane
into deeper layers of the tissue matrix, a procedure that has
been successfully used before in a lung cancer model.12
In summary, our aim is to generate an artificial colorectal
cancer tissue model. This should be achieved (1) by the in-
tegration of a biological tissue scaffold, including basement
membrane structures, (2) by the interaction of tumor cells
with the tumor stroma, and (3) by applying advanced biore-
actor technologies. Our new cancer model paves the way for
in vitro analyses of drug efficacy that reflect characteristics of
human tumor tissue at different stages of malignancy.
Materials and Methods
Cell lines and 2D cell culture
SW480 and Caco2 cells were bought at DSMZ. SW480
cells were cultured in RPMI +10% fetal calf serum (FCS)
and Caco2 cells in MEM + 20% FCS+ 1% NEAA + 1%
Pyruvate. Cells were monitored for pathogen infections at
regular intervals. For immunohistochemical 2D stainings,
cells were seeded on glass slides until they had reached a
confluency of about 70%.
Human fibroblasts
Fibroblasts were isolated from skin biopsies derived from
the University Hospital Wuerzburg (ethics proposal: 182/10).
Skin biopsies were rinsed with phosphate-buffered saline
(PBS) with calcium and magnesium (0.5 g MgCl2$6H2O+
0.5 g CaCl2/5L PBS) before all fat and tissue remnants were
removed. After a second rinsing with PBS+calcium and
magnesium, the skin was cut into strips of 2–3mm width.
Strips were rinsed with PBS and covered with 2U/mL dis-
pase solution (Invitrogen) over night at 4C. Then, the dis-
pase solution was removed and 10mL PBS with calcium and
magnesium (0.5 g MgCl2$6H2O+ 0.5 g CaCl2/5L PBS) was
added. Epidermis and dermis were separated mechanically.
Dermis strips were transferred to a new Petri dish, chopped
into small pieces, and incubated in 5mL of collagenase so-
lution (500U/mL) in a 50-mL tube. The Petri dish was re-
rinsed with 5mL of collagenase solution, which was then put
into the 50-mL tube containing the chopped pieces of dermis.
They were first incubated for 45min at 37C and then
centrifuged for 5min at 1200 rpm. Supernatant was removed
and the remaining pellet was resuspended in 2mL of culture
medium and transferred to a T75 cell culture flask. The next
day, 2mL of culture medium was added.
SISmuc preparation
SISmuc was prepared from porcine jejunal segments and
consists of small intestine submucosa (SIS) and mucosa
(muc). All explantations were in compliance with the Ger-
man Animal Protection Laws (x4 Abs.3) and the institute’s
animal protection officer regularly informed the responsible
authorities. The animals received proper attention and
humane care in compliance with the Guide for Care and Use
of Laboratory Animals published by the National Institute of
Health (NIH publication no. 85e23, revised 1996) and as
approved of by the institutional board of animal protection.
After jejunum explantation, the scaffold was prepared as
previously described.13–15 The SISmuc was generated by
removing the mesentery with the vascular tree from the
completely decellularized explant.
3D cell culture of in vitro models
For static 3D cell culture, cells were seeded onto the
SISmuc (see porcine material), fixed between two tailored
metal rings—the cell crowns (Fig. 1). All 3D cell cultures
were performed under standard conditions (37C, 5% CO2)
as described before.12,16 For monocultures, 100.000 cells in
500 mL medium were seeded onto the former luminal side of
the SISmuc scaffold. For cocultures, 100.000 tumor cells
and 100.000 fibroblasts were seeded together in 500mL
medium onto the SISmuc scaffold. After an adhesion time
of 2 h, cell crowns with reseeded scaffold were completely
filled with medium and cultured for 14 days. Then, the tissue
was washed with PBS and fixed in 4% paraformaldehyde
(PFA) for 2 h followed by paraffin embedding in an
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automated system (STP 120; Thermo Fisher Scientific
GmbH) for immunohistochemical analysis. Other samples
were frozen without any fixation to isolate mRNA from the
cells for quantitative real time-PCR (qRT-PCR) analysis.
For dynamic 3D cell culture, SW480 cells were seeded
in monoculture and in coculture with dermal fibroblasts
onto SISmuc scaffolds and placed in cell crowns 3 days
before starting the bioreactor culture (Fig. 2), thus allowing
the cells to attach to the scaffold. Afterward, the scaffolds
were transferred to the bioreactor and were cultured under
dynamic conditions maintaining a constant medium flow
for another 10 days. The speed of the blood flow was ad-
justed to a speed of 3–4 · 10-3 mL/min exerting mechan-
ical shear stress on the constructs (Fig. 2D). For the
dynamic cell culture, 1% of Pen/Strep was added to the
cell-specific medium.
Bioreactor
The bioreactor (Fig. 2A) was designed to allow the cul-
ture of tissues at the interface between two separated fluid
circulation systems. For the design of tailored parts, Solid-
Works 2010 · 64 Edition (Dassault Systemes Deutschland
GmbH) was used. Construction drawings were sent to GT
Labortechnik and parts were manufactured from poly-
sulfone (PSU). To identify an optimal bioreactor setup,
different designs were investigated by computational mod-
eling (Fig. 2B, C). For this, COMSOL Multiphysics
(Comsol Multiphysics GmbH) was used. Bioreactor geom-
etries were transferred to the simulation software, and the
fluid domains were parameterized as water at 37C. In ad-
dition, inlet regions with a specific flow velocity and outlet
regions exhibiting ambient pressure conditions were de-
fined. By varying the inlet velocity and by calculating the
shear stress distribution, the characterization of a bioreactor
design and the identification of the bioreactor operating
range were made possible (Fig. 2D).
Stimulation with 5-fluorouracil
Static models were treated with 25mM (3.25 mg/mL) 5-
fluorouracil (5-FU) (Selleckchem) on day 7, 10, and 13.
FIG. 1. 3D cell culture in a static
system. The SISmuc scaffold
derived from a porcine jejunum is
fixed between two metal rings, the
cell crown. Cells are seeded onto
the scaffold and cultured in 12-well
plates. For coculturing of tumor
cell lines with primary fibroblasts,
fibroblasts are isolated from the
dermis of human skin biopsies and
seeded onto the scaffold together
with the tumor cells. 3D, three-
dimensional; SISmuc, small in-
testinal submucosa with preserved
mucosa. Color images available
online at www.liebertpub.com/tec
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Dynamic cultured models were treated on day 7 and 11 of
dynamic cell culture with 25 mM 5-FU. On day 14 of static
or dynamic cell culture, tissue was fixed in PFA and em-
bedded in paraffin for immunohistochemistry. Cell Titer Glo
Cell Viability Assay (Promega) was performed with 2D
cultured cells following the manufacturer’s protocol.
Fluorescence immunohistochemistry
Glass slides were fixed in 4% PFA for 10min and SISmuc
samples for 2 h. After fixation, glass slides were either
directly stained or stored in PBS buffer at 4C for up to
1 week before staining. SISmuc samples were stained as
paraffinized sections (3–5mm) and primary antibodies (E-
cadherin No. 610181, BD Transduction Laboratories; b-
Catenin No. ab32572, AbCam; Vimentin No. ab92547,
AbCam; PCK No. C 2562-.2ML, Sigma-Aldrich Chemie
GmbH; Ki67 No. ab16667, AbCam; Collagen IV No.
ab6586, AbCam) were diluted 1:100 and incubated over
night at 4C. Secondary antibodies were diluted 1:400 and
incubated for 1 h at room temperature. Double stainings
were performed by using primary antibodies of two different
species and secondary antibodies marked with the fluores-
cent dyes, Alexa-647 or Alexa-555 (Life Technologies
GmbH). Nuclei were counterstained by DAPI solved in
Mowiol embedding solution. Pictures were taken by using
either a confocal laser scanning microscope (SP-8; Leica
Microsystems GmbH) or a digital microscope (BZ-9000;
Keyence Deutschland GmbH).
Diaminobenzidine immunohistochemistry
SISmuc samples were stained as paraffinized sections (3–
5 mm) with Villin (#V1616C01; DCS) according to the in-
structions of the EnVision+System-HRP (Diaminobenzidine
[DAB]) (Dako Deutschland GmbH).
FIG. 2. Compartmented bioreactor for the culture of tissues at the interface between two fluid circulation systems. (A)
The bioreactor comprises a tissue chamber, a peristaltic pump, and a reservoir container for the cell culture medium.
From the reservoir container, the peristaltic pump delivers cell culture medium to the tissue chamber harboring up to
three tissue constructs in separated compartments. (B) A sectional view of such a compartment depicts the path of the
flow allowing defined shear stress conditions. On both sides of the tissue, independent fluid circulations ensure apical-
and basolateral-specific culture conditions. Stainless steel electrodes support the electrical characterization of the cul-
tured tissue. (C) The streamline and the resulting shear stress on the tissue surface at an inlet volume flow of 3.8mL/min
were predicted using computational modeling. Except from a ring of *50 mm at the tissue–bioreactor interface, shear
stress values between 3.0 and 5.0 · 10-3 N/m2 were calculated. (D) By varying the inlet volume flow, the operating range
of the bioreactor was characterized to allow the prediction of the average shear stress at a specific velocity of the inlet
volume flow. According to the operating range, average shear stress at a volume flow of 3.8mL was calculated to
3.34 · 10-3 N/m2. Color images available online at www.liebertpub.com/tec
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Quantitative real time-PCR
We isolated total mRNA from cells using the RNeasy
Micro Kit (QIAGEN). The synthesis of cDNA was done by
using the iScript Kit (Bio-Rad Laboratories GmbH). We
used the following primers in a 2-step PCR with the Sso-
Fast EvaGreen Supermix (BioRad):
Vimentin: CTGGATTTCCTCTTCGTGGA and CGAAAA
CACCCTGCAATCTT,
E-cadherin: GACCGGTGCAATCTTCAAAA and CAGGT
CTCCTCTTGGCTCTG,
GAPDH: TGACGCTGGGGCTGGCATTG and GCTCTT
GCTGGGGCTGGTGG,
FIG. 3. In conventional 2Dcell culture, SW480cells displaya lessdifferentiatedandmoremalignant phenotype thanCaco2cells.
In 2Dcell culture, phase-contrast pictures show that SW480 cells roundup and lose contactwith the bottomof the culture flask (A1),
whereas Caco2 cells display awell-differentiatedmonolayer (A2). Immunofluorescence double stainings of vimentin (red right top
inB,E) and PCK (green right top inB, E) indicate a higher expression of the mesenchymal marker vimentin in SW480 (B) than in
Caco2 cells (E), which was confirmed and quantified by qRT-PCR (D). Immunofluorescence double stainings of the adherence
junction protein E-cadherin (green right bottom inC, F) and b-catenin (red right top inC, F) demonstrate a lower expression of E-
cadherin in SW480 (C) than in Caco2 cells (F). b-Catenin localizes in the nucleus of several SW480 cells (C, arrows). E-cadherin
expression could be also confirmed and quantified by qRT-PCR (D). Scale bars in (B–F): 25mm. 2D, two-dimensional; PCK, Pan-
cytokeratin; qRT-PCR, quantitative real time-PCR. Color images available online at www.liebertpub.com/tec
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HPRT: TGACCTTGATTTATTTTGCATACC and CGAG
CAAGACGTTCAGTCCT. Genes were normalized to HPRT
and GAPDH and the DDCT method was used for evaluation
of expression ratios. Primer efficiencies were 91–95%.
Results
Caco2 and SW480 colorectal cancer cell lines allow
mimicking of different tumor stages
To establish an in vitro tissue-like 3D tumor model that
can simulate tumors in different malignant stages, two dif-
ferent cell lines with reportedly more differentiated (Caco2)
or undifferentiated (SW480) growth behavior were tested.
Phase-contrast pictures in conventional cell culture showed
a stronger adherence to the standard culture flasks in Caco2
cells than in SW480 cells. SW480 cells tended to round up
and to separate from the surface, whereas Caco2 cells built a
tight monolayer (Fig. 3A1, A2). Compared to Caco2 cells,
the more malignant SW480 cells showed a higher expres-
sion of vimentin in immunofluorescence staining, thus in-
dicating an initiated EMT process going along with a lower
expression of the adherence junction marker E-cadherin.
This was confirmed quantitatively by qRT-PCR (Fig. 3D).
We noted that in some of the SW480 cells, but not in any
Caco2 cells, b-catenin was localized within the nucleus
(Fig. 3C, arrows), indicating a more malignant state of
SW480 cells.16
Generation of 3D tumor models
For 3D in vitro colon cancer tumor model development,
we applied the SISmuc as a scaffold with intestinal micro-
architecture as used before for artificial tissue and lung
tumor models.12,14 First, we determined a cell number of
1 · 105 Caco2 cells and a culture period of 14 days on our
SISmuc scaffold as being optimal to generate artificial tissue
with epithelial characteristics. We could demonstrate dif-
ferentiation progress by immunohistochemical staining of
villin. This protein involved in absorption was basolaterally
located after 7 days of culture (Fig. 4A) and moved to the
apical surface of the epithelial monolayer after 14 days of
culture (Fig. 4B). Furthermore, transmission electron mi-
croscopy (TEM) analysis revealed the formation of regular
microvilli, close cell-to-cell contacts with apical tight
junctions (arrow in Fig. 4d), the presence of storage vacu-
oles,17 and a close attachment to the preserved basement
membrane of the decellularized intestinal scaffold (Fig. 4C–
E). The same culture conditions that allowed well-
differentiated growth of Caco2 cells were applied to SW480
cells in the following experiments as well as to the coculture
approaches with primary fibroblasts.
FIG. 4. On the 3D SISmuc scaffold, differentiation of Caco2 cells is achieved after 14 days of culture. Immunohistochemical
DAB-staining of villin on paraffin sections shows a basolateral/cytoplasmic location after 7 days of cell growth (A) and its
change to the apical side after 14 days of growth (B, arrows). Ultrastructural analysis of Caco2 cultured on SISmuc for 14 days
displays a closedmonolayer on top of the SISmuc. The cells show a well-differentiated morphology ofmicrovilli (C,D: mv), the
formation of close apical tight junctions (arrow in d) aswell asmucin-vacuoles (v inD). The nucleus ismarkedwith n.Moreover,
cells attach to the preserved basement membrane (*= lamina lucida,  = lamina densa) of the SISmuc (e). Arrow in (E): collagen
fibers. DAB, diaminobenzidine. Color images available online at www.liebertpub.com/tec
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The percentage of proliferating cells in 3D cell culture
resembles the in vivo situation
In our 3D in vitro tumor model for colorectal carcinoma, we
were able to show a clearly decreased proliferation by im-
munohistochemical Ki67 staining. Compared to almost 100%
Ki67-positive cells in conventional 2D cell cultures of Caco2
and SW480 cells (Fig. 5A, B), lower cell proliferation ap-
peared in 3D cultures of both tumor cell lines (Fig. 5C, D). The
percentage of proliferating cells in patients’ biopsies from
different tumor stages in the tumor center and border ranged
from 6% in UICC I, 16% in UICC II, 32% in UICC III, to 35%
in UICC IV. To find out if markers from 2D stainings were
maintained in 3D and could be aligned to morphological
growth patterns indicating invasion or metastasis formation,
we investigated tissue morphology by hematoxylin and eosin
(HE) staining and stained for molecular EMT markers such as
Pan-cytokeratin (PCK) and vimentin, epithelial differentiation
(E-cadherin), and nuclear b-catenin localization.
Tissue microenvironment and fibroblast coculture
enhance differences of tumor characteristics in Caco2
and SW480 cells
As demonstrated by HE stainings, Caco2 cells formed a
monolayer on top of the scaffold (Fig. 6A). Primary fibro-
blasts exhibited a flat cell morphology and grew inside the
scaffold. The former villi topography of the SISmuc was
remodeled to a plain surface (Fig. 6B). In contrast to the
Caco2 cells, more malignant SW480 cells grew chaotically
without the formation of a closed monolayer and migrated
more deeply into the former crypt and vessel structures of
the gut. Moreover, single SW480 cells completely lost
contact with the scaffold (Fig. 6C). The immunofluores-
cence analysis of vimentin and PCK showed a high ex-
pression of PCK in Caco2 cells and vice versa, a high
expression of vimentin in fibroblasts (Fig. 6D, E). We noted
that in contrast to 2D conditions, vimentin could no longer
be detected in SW480 cells cultured on SISmuc (Fig. 6F,
compare to inset). In our coculture model, we seeded the
same number of tumor cells and fibroblasts at the same time
onto the SISmuc scaffold. Interestingly, fibroblasts from the
same batch affected Caco2 and SW480 cell growth and
morphology differently. After 2 weeks in coculture with
fibroblasts, Caco2 cells formed multilayers in single areas.
However, HE staining revealed no morphological changes
compared to monocultures (Fig. 6G). On the contrary, fi-
broblast coculture showed a strong morphological impact on
SW480 cells and resulted in the formation of tumor-like
nodes (Fig. 6H). Cocultures with both cell lines showed less
protruding villi structures similar to fibroblast monocultures.
FIG. 5. The amount of
proliferating cells in the 3D
in vitro tumor model de-
creases compared to conven-
tional 2D cell culture and
correlates better to low-grade
(UICC I) and high-grade
(UICC IV) tumors. Ki67 im-
munofluorescence staining of
Caco2 cells (A) and SW480
cells (B) in 2D cell culture
demonstrates a high prolifer-
ation that decreases distinctly
in 3D cultures of Caco2 (C)
and SW480 cells (D). The
number of proliferating cells
cultured under 3D culture
conditions correlates more
precisely with those found in
tumors with a low (E, G) and
high grade (F, H) of malig-
nancy. Pictures were taken
from the tumor border (E, F)
as well as from the center of
the tumor (G, H). Scale bar
in (D) represents 75mm for
(A–D). Scale bar in (F) rep-
resents 50 mm for (E–H).
Color images available online
at www.liebertpub.com/tec
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Evidently, neither the seeding order nor a higher ratio of
fibroblasts impaired the overall coculture morphologies
(data not shown). Depending on the tumor cell type, PCK/
vimentin fluorescence double staining demonstrated that
fibroblasts and tumor cells were located in different regions
of the SISmuc in 3D cell culture (Fig. 6I, J). In Caco2
cocultures, fibroblasts accumulated inside the matrix, clearly
separated from the tumor cells on top (Fig. 6I). In SW480
cocultures, fibroblasts grew on the surface of the matrix, at
the interface separating mucosa and submucosa, between the
tumor-like nodes and also in close association to them
(Fig. 6J). SW480 and fibroblasts could be distinguished by
morphological features and by vimentin staining, since
downregulation of vimentin was maintained in SW480 co-
culture settings.
Epithelial characteristics of SW480 cells are more
prominent in the 3D microenvironment
Next, we correlated our morphological observations to the
expression of E-cadherin as a MET-marker and to the ex-
pression of b-catenin. As expected, we could show by confocal
analysis of E-cadherin/b-catenin immunofluorescence double
staining that both colocalize in 2D Caco2 monocultures at the
cell junctions. This was not changed by the coculture with
fibroblasts in 3D (Supplementary Fig. S1; Supplementary Data
FIG. 6. Fibroblasts induce tumor
cell aggregation of SW480 on the
SISmuc scaffold. HE staining of
paraffin sections of the 3D in vitro
tumor model shows that Caco2
cells grow as a monolayer (A),
while SW480 cells exhibit a less
differentiated phenotype with loose
cell-to-cell contacts (C). Within
both cell lines, former crypt (c) and
villi (v) structures remain clearly
visible. In contrast to this, fibro-
blasts remodel the matrix to a flat
layer without villi structures (B).
PCK/vimentin double immunoflu-
orescence staining demonstrates a
strong PCK staining of Caco2 and
SW480 cells (D, F), and a high
expression of vimentin in fibro-
blasts (E). Vimentin expression is
lost in SW480 in 3D culture con-
ditions compared to 2D conditions
(F, inset: 2D staining: PCK/vi-
mentin). HE staining of cocultures
indicates a preserved monolayer
formation of Caco2 cells even
though in some parts, multilayers
could also be observed (G). In
SW480 cocultures, the morphology
of tumor cells changed to tumor
tissue-like aggregates inside the
matrix (H, arrows). Immuno-
fluorescence double staining of
PCK/vimentin shows that in Caco2
cocultures, the fibroblasts stay in
the bottom compartment with the
tumor cells on top (I), whereas in
SW480 cocultures, the tumor cells
are enclosed by fibroblasts that
grow on top, beneath, and between
the tumor nodes ( J). HE, hema-
toxylin and eosin. Color images
available online at www.liebertpub
.com/tec
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are available online at www.liebertpub.com/tec). In contrast to
that, a weaker expression of E-cadherin and concentration in
areas of cell aggregates were found in SW480 monocultures
(Fig. 7A, stars). In coculture, E-cadherin accumulated in tumor-
like nodes at the cell borders (Fig. 7B). b-Catenin expression in
mono- and cocultures was more pronounced in SW480 cells
than in Caco2 cells (compare Supplementary Fig. S1). More-
over, in SW480monocultures, b-catenin was observed in some
single cells inside the nucleus (Fig. 7A, arrows), whichwas also
visible in 3D coculture samples (Fig. 7B). In addition, in sev-
eral other areas of the artificial tumor tissue generated by
SW480 cells and fibroblasts, a yellow staining indicative of
colocalization appeared in the merged staining of E-cadherin
and b-catenin (Fig. 7B arrowheads).
Dynamic cell culture conditions support tumor tissue
generation and association with the tumor–stroma
To ensure an optimal in vivo-like nutrient supply and
waste removal, we applied dynamic culture conditions to
SW480 mono- and cocultures using a newly constructed
flow bioreactor system (Fig. 2). These conditions enhanced
SW480 tumor cell growth during a culture period of
14 days. As a result, SW480 filled all the former crypts and
built multilayers on the former villi (Fig. 7C, E, G). In
contrast to that, SW480 cocultured with fibroblasts re-
modeled the SISmuc and changed the crypt structure as
shown by E-cadherin/b-catenin double staining (Fig. 7D) as
well as HE staining (Fig. 7F) and PCK/collagen-IV double
staining (Fig. 7H). E-cadherin staining displayed quite a
homogenous distribution within the areas of cells tightly
packed together in monoculture (Fig. 7C) as well as in co-
culture (Fig. 7D). In contrast to the dynamic SW480
monoculture, where single cells express b-catenin in the
cytoplasm, the majority of cells in the dynamic coculture
setting expressed b-catenin only at the cell borders
(Fig. 7D). The formation of a tumor-like tissue with a sur-
rounding tumor stroma was demonstrated by PCK/vimentin
double staining to differentiate between tumor tissue and
surrounding fibroblasts (Fig. 8). Tumor cell aggregates were
FIG. 7. In coculture with fibro-
blasts, the crypt structure of the
SISmuc is changed by the SW480
tumor cells. In static SW480
monoculture, b-catenin (red in A–
D) localizes in the cytoplasm and
the nucleus of several cells (arrows
in A). E-cadherin (green in A–D)
staining shows single areas of
strong expression within cell ag-
gregates (stars in A). In static co-
culture of SW480 and fibroblasts,
E-cadherin staining is more pro-
nounced, especially in SW480 ag-
gregates, and is partly colocalized
with b-catenin (arrowheads in B).
Under dynamic culture conditions
in the flow bioreactor, this effect is
enhanced in the coculture (D)
compared to monoculture (C).
While in monoculture, SW480 tu-
mor cells fill the former crypts of
the SISmuc scaffold and preserve
the regular structure of the gut, the
former crypt structure is remodeled
by the cells in coculture with fi-
broblasts (D). This effect is more
visible in HE staining (E, F) as
well as in a double staining of PCK
(green in G, H, tumor cells) and
collagen-IV (red in G, H, basement
membranes). Scale bars in (A–C)
represent 75mm. Scale bars in
(E–H) represent 500 mm. Color
images available online at
www.liebertpub.com/tec
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enclosed by fibroblasts and tumor cells completely overgrew
the SISmuc in several parts of the scaffold (Fig. 8A, B). The
morphology of the generated tissue closely resembled that
of a colon adenocarcinoma (Fig. 8C).
Fibroblasts remodel basement membrane structures
under dynamic cell culture conditions
To analyze basement membrane structures, we stained
dynamically cultured SW480 mono- and cocultures for
collagen-IV. The tumor cells alone (marked by PCK, green
in Fig. 9) did not change the collagen structure of the SIS-
muc (Fig. 9A–C). Around former crypts, basement mem-
branes are precisely visualized by anticollagen-IV staining
and mostly well preserved (Fig. 9B, arrows). In coculture
with fibroblasts (Fig. 9D–F), these distinct borders are in-
terrupted (Fig. 9E, arrow) and the red collagen-IV staining
shows a thickened structure of the SISmuc (Fig. 9E, F).
Fibroblasts are able to remodel the SISmuc alone (Fig. 9G,
H) as well as in coculture with SW480 (Fig. 9D–F). In
coculture, fibroblasts (stained by vimentin, red in Fig. 9J, K)
intermingle with the tumor cells (stained by PCK, green in
Fig. 9J, K) and, in some areas, seem to lead them deeply into
the collagen structure of the SISmuc (Fig. 9K).
5-FU treatment reduces tumor cells under static
and dynamic conditions in coculture settings
with primary fibroblasts
SW480 cells were nearly insensitive to 5-FU under 2D
culture conditions (Supplementary Fig. S2A) and static 3D
monocultures (Supplementary Fig. S2C). In contrast to this,
the treatment of cocultures with 25mM 5-FU resulted in de-
creased tumor cell numbers as clearly shown by a PCK/vi-
mentin staining under 3D static culture conditions (green in
Fig. 10A, C), as well as under 3D dynamic culture conditions
(Fig. 10C, D). In fibroblasts, we observed no effect of this
treatment in monocultures (red in Supplementary Fig. S2C)
and in cocultures (red in Fig. 10B, D). In coculture of SW480
with fibroblasts, the dense clusters of tumor cells surrounded
by fibroblasts shrank and became less compact after a treat-
ment period of 1 week. In the untreated controls, many living
cells were flushed into the medium reservoir, but we found
only dead tumor cells in the medium reservoir of bioreactors
FIG. 8. The 3D colon cancer
model with integrated fibroblasts
phenocopies a patient’s colon ade-
nocarcinoma. PCK (green) and vi-
mentin (red) fluorescence double
staining demonstrates a close as-
sociation of SW480 tumor cells
(PCK positive) with cocultured fi-
broblasts (vimentin positive) in a
dynamic bioreactor culture. This
phenotype reflects the morphology
of a colon adenocarcinoma from a
patient’s biopsy (C). Scale bars:
50 mm in (A, C) and 100mm in (B).
Color images available online at
www.liebertpub.com/tec
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treated with 5-FU (data not shown). In 2D, the coculturing of
cells resulted in a fibroblast monolayer with single tumor
cells placed on top and no tumor cell aggregates could be
observed (Supplementary Fig. S2B, C).
Discussion
We developed a histologically complex 3D intestinal
colon cancer model, including a tumor–stroma, on the basis
of the biological collagen scaffold SISmuc, which has al-
ready been used for a lung tumor test system12 and which
derives from the BioVaSc.
Our tissue-engineered 3D model reflects different aspects
of tumors on morphological and molecular levels: (1) the
formation of a differentiated monolayer of human Caco2
colon cancer cells in contrast to a more scattered growth
pattern of SW480 cells accompanied by a loss of vimentin
when cultured in 3D, (2) a reduction of the proliferation
correlative to clinical samples, (3) the induction of tumor-
like structures of malignantly growing SW480 tumor cells
by coculture with fibroblasts destroying basement mem-
brane integrity that was not observed in Caco2 cocultures,
and (4) the generation of a tight tissue-like association of
tumor cells with each other and with the fibroblasts under
dynamic culture conditions in a bioreactor. The resulting
artificial tumor tissue with stroma resembles native adeno-
carcinomas and a clinically relevant treatment with 5-FU
could be tested as a proof of principle.
By culturing tumor cells in 3D conditions on our matrix,
their proliferation strongly decreases. Although an increase
FIG. 9. In coculture with
fibroblasts, the SISmuc scaf-
fold is remodeled, and fibro-
blasts grow at the tip of
tumor cells. The tumor cells
alone (marked by PCK,
green) do not remodel the
collagen structure of the
SISmuc (A–C). The base-
ment membrane of the for-
mer crypts is clearly visible
by immunohistochemical
staining of collagen-IV (red
in A–I) and is not interrupted
(arrows in B). In coculture
with fibroblasts (D–F), the
distinct border of the former
crypts is only partially visible
(arrow in E) and the SISmuc
is compacted with collagen-
IV (E, F). In monoculture,
the fibroblasts remodel the
SISmuc (G, H). In some
areas of the coculture, fibro-
blasts (stained by vimentin,
red in J, K) intermingle with
the tumor cells (stained by
PCK, green in J, K) and
grow in front of them into the
collagen structure of the
SISmuc (K). Scale bars in
(G–I) represent 25 mm for
(A–I). Scale bars in ( J) and
(K) represent 25 mm. Color
images available online at
www.liebertpub.com/tec
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in the percentage of proliferating cells can be seen in some
metastases where the Ki67 index has been identified as a
prognostic marker,18 the number of proliferating cells is
usually lower in most tumors. Concerning cytostatic drugs,
our model should thereby reduce false-positive results in
preclinical testing that are thought to be derived at least, in
part, from artificially high proliferation rates up to 90 or
even 100% in 2D culture.19
In 1998, Kammerer et al. tested a similar decellularized
human colonic matrix for the development of tumor mod-
els.20 They stressed the potential of decellularized tissue
scaffolds as they included parts of the decellularized human
colon as basis for tumor and stroma generation. However,
they did not succeed with further developments. In the
present study, we used a jejunal segment of porcine origin,
which has several advantages. We developed a standardized
tumor model based on the SISmuc, which is a non-
vascularized part of the BioVaSc. This model can be vas-
cularized in future settings by reseeding human endothelial
cells into the preserved vessel structures as done before.21,22
The jejunal compartment is superior to colon tissue as it
exhibits a higher vascularization and contains significantly
less bacteria. This facilitates the decellularization process in
bioreactors and the creation of a sterile scaffold, a fact of
major importance as the use of sodium deoxycholate for
decellularization hinders the addition of antibiotics. More-
over, the jejunum is much longer than the colon and thus
fewer animals have to be sacrificed.
Since evolution has produced a high conservation of
ECM proteins from porcine to human beings, it is even
possible to implant such constructs into patients after re-
cellularization of our scaffold with human cells.22 This in-
dicates that our porcine matrix is suitable for human tumor
model generation. Furthermore, porcine gut is easily ob-
tainable from commercial pig breeders, which facilitates the
production of pharmaceutical test systems.
Caco2 cells are well established for applications in 3D
cell culture models that simulate the intestinal barrier and
are used for drug uptake studies.23,24 As shown before, they
exhibit a differentiated phenotype in a suitable microenvi-
ronment.25 To investigate to which extent our decellularized
tissue scaffold reflects tumor characteristics—especially
concerning invasion and metastasis—we focused on the
more malignant SW480 cell line. In fact, the 3D microen-
vironment showed a stronger impact on SW480 cells than
on Caco2 cells as marked by a downregulation of vimentin
indicating MET induction—a hallmark for metastasis gen-
eration.9
Remarkably, coculture with fibroblasts induced only
SW480 cells to form tumor-like cell clusters with fibroblasts
within the matrix, whereas Caco2 cells grew on top of the
matrix separated from the fibroblasts beneath. In some areas,
we observed the generation of multilayers as found in hyper-
plastic epithelial regions: one of the first steps in tumorigen-
esis. This indicates different cell-specific interactions of both
tumor cell types with the same fibroblast population and
stresses the impact of signaling circuits between the tumor–
stroma and the tumor cells on tumor formation. It is widely
recognized that the tumor–stroma plays a key role in tumor
growth and invasion by the secretion of degrading enzymes
and by storing cytokines.6,26 This changes signaling and
thereby drug response in different invasive states.27 In fact,
colon cancer tissue usually displays a very large proportion of
fibrotic tissue.28,29 These issues further emphasize the impor-
tance to include the stroma component in preclinical tumor
models.
To test the robustness of the system, different seeding
conditions were compared such as different ratios of tumor
cells to fibroblasts, different orders of seeding, first the fi-
broblasts and then the tumor cells or vice versa, as well as
different donors of primary fibroblasts. Similar morpho-
logical results were observed in all the different experi-
mental settings (data not shown). For standardization, we
seeded both kinds of cells at the same time to generate the
test model.
On a molecular level, we investigated the differentiation
status and the degree of EMT by E-cadherin/b-catenin and
PCK/vimentin fluorescence double staining, respectively. In
healthy epithelia, b-catenin is linked to E-cadherin at the
cell border connecting it to the actin cytoskeleton. In pri-
mary tumors, E-cadherin expression is reduced and trans-
locates to the cytoplasm at the invasion front. b-Catenin
dissociates from E-cadherin and also translocates to the
cytoplasm as well as into the nucleus. In this study, it
FIG. 10. Treatment of SW480 in coculture with fibroblasts
with 25mM 5-FU under static as well as dynamic conditions.
Under static culture conditions (A, B), treatment with 5-FU
results in decreased tumor cell numbers (green) but leaves
fibroblasts (red) unaffected (B). The same effect can be seen
under dynamic conditions (C, D) where tumor cell numbers
are much higher in the untreated control (C) compared to the
treated sample (D). Scale bar in D: 100mm for (A–D). PCK:
green, vimentin: red, DAPI: blue. 5-FU, 5-fluorouracil. Color
images available online at www.liebertpub.com/tec
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induces the expression of other genes important for EMT
and inhibitors of apoptosis, as reviewed concisely by Lee
et al.30 Nuclear localization of b-catenin correlates with a
poor prognosis in the clinic.31 In colorectal carcinogenesis,
many pro-oncogenic factors encourage b-catenin translo-
cation from the adherens junction to the nucleus, and anti-
oncogenic factors inhibit nuclear b-catenin signaling. This
stresses its vital part in tumor development.32 When me-
tastases extravasate into distant healthy tissues to form a
macroscopic secondary tumor, cancer cells have to cross the
basement membrane and revert to an epithelial state in a
process that is called MET and a strong E-cadherin ex-
pression is found in these areas.33
Our 3D SW480 colon cancer model showed strong E-
cadherin expression particularly in areas of dense tumor cell
aggregate formation. This effect was more pronounced in a
flow bioreactor under dynamic conditions enhancing close
cell associations. Furthermore, we observed a strong
downregulation of vimentin expression in 3D compared to
2D culture—under static as well as dynamic conditions. Since
SW480 cancer cells are known to develop more epithelial
characteristics at a higher confluency,34 this effect could be
related to a higher confluency in the 3D cell culture. Thus, the
induction of tighter cell to cell contacts in 3D cell culture
conditions could trigger MET induction, as it takes place in
tissues into which metastases originating from circulating
single tumor cells grow. The MET process characterized by
E-cadherin re-expression is thought to be a critical step dur-
ing metastasis formation, as reviewed by Wells et al.33
As mentioned before, at least two different mechanisms
exist for tumor cell invasion where fibroblasts play a central
part. First, fibroblasts are important for single-cell invasion
because this needs the EMT of tumor cells induced by
myofibroblasts of the adjacent tumor–stroma.35,36 Second,
they are also essential for collective invasion processes37 as
they are able to remodel the scaffold and to guide tumor cells
through this matrix. Accordingly, in deep layers of the col-
lagen scaffold, we could observe patterns of fibroblasts in
front of bulky tumor cell formations. In contrast to single-cell
invasion, collective invasion is considered to be independent
of EMT in tumor cells and to be associated with fibroblasts.
The mesenchymal marker vimentin is not reactivated in
SW480 cells in the coculture setting, indicating no EMT in-
volvement in this process, thus supporting the hypothesis that
collective invasion is taking place in our model.
As a conclusion, we could generate a model for a more
advanced tumor stage for which only a limited number of
models are available—even though such patients need the
most support.
To show that our model is a useful tool in preclinical
testing, we performed drug response analyses with 5-FU as a
commonly applied drug in colon cancer treatment.38 In
contrast to monoculture settings under 2D and 3D condi-
tions, we could show that a 5-FU treatment decreased the
number of tumor cells under static as well as dynamic 3D
conditions in coculture with fibroblasts. A low sensitivity of
SW480 cells to 5-FU has been reported in several studies
before,39–41 even though this drug is a standard therapy in
the clinic. This again stresses the tremendous importance of
integrating stromal components into test systems to reveal
reliable predictions correlating to the patients’ situation in
the clinic. In 2D cell culture, coculturing of SW480 cells
and fibroblasts failed to generate close tumor-fibroblast ag-
gregates and fibroblasts overgrew the tumor cells after a
short culture period.
In the clinic, a mono-therapy—also in high plasma con-
centrations42—with 5-FU leads to a limited treatment re-
sponse but in the end to unsatisfactory results in most
cases.43 Therefore, 5-FU is applied mostly in combination
with other substances such as folinic acid (FA).38,44–46 In
future, other substances, for instance, a combination of 5-FU
and FA, could be tested by using our artificial tissue, which
is morphologically similar to colorectal adenocarcinoma
metastases.
Outlook
This 3D model for colorectal tumors is directly available
for drug testing since fundamental work has already estab-
lished a standard operating protocol for lung tumor tissue
generation and the quantitative measurement of drug re-
sponses regarding apoptosis and proliferation.12 In this
model, apoptosis is quantified from supernatants by an M30
ELISA, which specifically recognizes epithelial cell apo-
ptosis, thereby excluding fibroblasts. Double staining of
Ki67 and the epithelial marker PCK enables the assessment
of tumor cell proliferation in a coculture setting. This model
can become more sophisticated by using the standardized
biological scaffold BioVaSc-TERM,14 which allows vas-
cularization of tumor models. In serial bioreactors, this
would also enable the investigation of the metastatic spread
of single tumor cells into the artificial ‘‘blood’’ circulation
following the process of MET, which is a critical step in
metastasis.
SW480 colon cancer cells harbor an activating KRAS
mutation that occurs in 30–40% of colorectal cancer,47
making them insensitive to epidermal growth factor receptor
(EGFR) inhibitors.48 In the clinic, patients with these muta-
tions are excluded from targeted therapies available against
the EGFR. Therefore, novel therapeutic strategies are ur-
gently needed for efficient intervention and could be gained
by analysis of signaling changes on a targeted treatment in
certain mutational backgrounds. These data could be inte-
grated in bioinformatics network analyses as done before in
the combined in vitro/in silico lung tumor model.12
Conclusion
In this study, we established a modular tissue-engineered
3D colon cancer model, including the adjacent tumor en-
vironment on a decellularized matrix. We were able to foster
cell growth and metastasis-like tissue formation by co-
culturing fibroblasts and tumor cells in a newly developed
bioreactor. This test system enables analyses of drug re-
sponses in advanced tumor stages, particularly of substances
that target tumor–stroma interactions.
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